Mark Awad

Chief, Thoracic Oncology, Memorial Sloan Kettering Cancer Center @MSKCancerCenter | Lung Cancer Immunotherapy Research | Tweets my own

[Mark Awad @DrMarkAwad]

@DiFedericoMD @BRicciutiMD @MSKCancerCenter @charlesrudin @IASLC @Unibo @DFarberThoracic @oncodaily @myESMO @pecci_federica1 Congratulations, Alessandro! So happy for you!!

[Federica Pecci @pecci_federica1]

Glad to share our work entitled "Brief Report: Critical Role for DNA-Based Sequencing in Discriminating Distinct Primary Lung Cancers With Different MET Exon 14 Skipping Mutations" published in @JTOonline
@DrMarkAwad Dr. Chaft and Dr. Agrawal

https://t.co/pOiPoseNuq

[OncoAlert @OncoAlert]

Brief Report: Critical Role for DNA-Based Sequencing in Discriminating Distinct Primary Lung Cancers with Different MET Exon 14 Skipping Mutations🧬

https://t.co/pSzxZy5b6D

This study evaluated NSCLC cases with MET exon 14 skipping (METex14) mutations using DNA-based sequencing to distinguish between recurrent disease and multiple independent primary tumors. Among 589 patients with METex14-mutant #NSCLC 🫁 112 had more than one tumor sample sequenced, and 8 patients were found to have two or more distinct primary lung cancers harboring different METex14 alterations. Both synchronous and metachronous tumors were identified, with comprehensive genomic profiling confirming their independent clonal origins.

These findings highlight the critical role of DNA-based sequencing, beyond RNA assays, in accurately staging patients with multiple METex14-mutant lung cancers to ensure appropriate clinical management. #LungCancer

@pecci_federica1
@JessieStuart316
@BiagioRicciutMD
@DiFedericoMD
@mihaela_aldea
@EdoardoGarbo
@valentsant
@dharadon99
@mkbaine
@sooryumyang
@paugalde20
@lmsholl
@DrMarkAwad
@ChaftJamie
@bmassutis
@ChristianRolfo @GlopesMd @NarjustFlorezMD @StephenVLiu @UmbertoMalapel1
@jillfeldman4 @Latinamd @JulienMazieres

#OncoAlertAF
@nataliagandur @acampsmalea @BRicciutiMD
@yekeduz_emre @HHorinouchi @FadiHaddad_MD
@Abdallah81MD @FernandoOnco
@ElisaAgostinett @to_be_elizabeth @bavilima @realbowtiedoc @Erman_Akkus @Lucarecco @GaiaGriguolo @JankovicK
@MarioBalsaMD @DrMirallas @GIMedOnc @OscarTahuahua @UOzkerim @DrRishabhOnco

[Mark Awad @DrMarkAwad]

@charlesrudin Dr. Charlie Rudin presenting positive overall survival results for tarlatamab in previously treated small cell lung cancer compared to 2nd line chemotherapy. #ASCO2025 @MSKCancerCenter

[Mark Awad @DrMarkAwad]

Congratulations to Dr. Jamie Chaft @ChaftJamie and co-investigators on the NeoADAURA clinical trial of neoadjuvant osimertinib in EGFR mutant lung cancer. #ASCO25 @EGFRResisters @MSKCancerCenter

[Mark Awad @DrMarkAwad]

Wonderful presentation from Dr. Alissa Cooper @alissajcooper on SEZ6 ADC ABBV-706 showing efficacy in diverse neuroendocrine tumors @MSKCancerCenter

[Mark Awad @DrMarkAwad]

Congratulations to Charlie Rudin & DeLLphi-304 investigators on this practice-changing trial for our patients with small cell lung cancer @MSKCancerCenter
Tarlatamab in SCLC after Platinum-Based Chemotherapy | New England Journal of Medicine https://t.co/tvSo0VYh9B

[Mark Awad @DrMarkAwad]

Congratulations to Kathryn Arbour @KCArbourMD and colleagues showing activity of BMS-986504 in MTAP-deleted solid tumors, including lung and pancreas cancer. @MSKCancerCenter

[Mark Awad @DrMarkAwad]

@OncLive @MSKCancerCenter A huge congratulations to Dr. Mark Kris @MSKCancerCenter, recipient of the 2025 Giants of Cancer Care award for thoracic oncology. He has tirelessly mentored so many of today's leaders in the field. #GiantsCC25

[Mark Awad @DrMarkAwad]

Thank you to our outstanding thoracic oncology team of physicians and reach staff @MSKCancerCenter for making such an impact on patient care through clinical trials #ASCO2025

[Mark Awad @DrMarkAwad]

Congratulations to Dr. Helena Yu and colleagues on their wonderful #ASCO2025 presentation on zipalertinib for patients with EGFR exon 20 insertion lung cancer. @Exon20Group @EGFRResisters @MSKCancerCenter

[Memorial Sloan Kettering Cancer Center @MSKCancerCenter]

We're excited to share that Dr. Andy Minn will return to MSK as the inaugural Chair of MSK’s new Immuno-Oncology Program in August.

This is a full-circle moment for Dr. Minn, a renowned physician-scientist, who completed his postdoctoral training with Dr. Joan Massagué, Director of the Sloan Kettering Institute (SKI), and his residency in the Department of Radiation Oncology, both at MSK, in 2003 and 2005 respectively.

Learn more about Dr. Minn: https://t.co/GygQ1f4pAo

[MSK Department of Medicine @MSK_DeptOfMed]

Congrats to Mark G. Kris, Kenneth Offit, David G. Pfister, and @szusmani on being inducted into the 13th Giants of Cancer Care® class by @OncLive! This award honors leading physicians who are advancing #cancerresearch. @MSKCancerCenter

Learn more: https://t.co/FcZdjNUeBa

[Mark Awad @DrMarkAwad]

Congratulations to Dr. Mark Kris @MSKCancerCenter for being named a Giant of Cancer Care for his many contributions to advancing the field of thoracic oncology! @OncLive #lcsm

https://t.co/t3zlVWvdcp via @onclive

[Memorial Sloan Kettering Cancer Center @MSKCancerCenter]

Join MSK thoracic medical oncologist Dr. Kathryn Arbour (@KCArbourMD) for a plenary session titled “Preliminary safety and antitumor activity of zoldonrasib (RMC-9805), an oral, RAS(ON) G12D-selective, tri-complex inhibitor in patients with KRAS G12D non-small cell lung cancer (NSCLC) from a phase 1 study in advanced solid tumors” TODAY at #AACR25. @AACR

Learn more: https://t.co/UQ05po7kzs

[Memorial Sloan Kettering Cancer Center @MSKCancerCenter]

In her plenary session at #AACR25, @AndreaCercek shared that PD-1 #immunotherapy can eliminate the need for surgery in patients with early-stage, DNA mismatch repair-deficient solid cancers. Learn more: https://t.co/dyCm86ou38 @AACR

[Memorial Sloan Kettering Cancer Center @MSKCancerCenter]

Congratulations to the MSK-IMPACT team at MSK for receiving the American Association for Cancer Research (AACR) Team Science Award.

The team, led by @MFBerger1, @DSolit, and @MLadanyi, is recognized for its pivotal advances in clinical genomic sequencing that have transformed oncology practice, clinical trials, and cancer discovery research. Learn more about this recognition: https://t.co/nz8QwNqcnF. #AACR25 @AACR

[LUNGevity Foundation @LUNGevity]

Ph1 trial of zoldonrasib (RMC-9805), an oral KRAS G12D inhibitor in pts w/ #NSCLC showed ORR of 61%. Side effects primarily gastro-intestinal. Great to see new options for this pt group. @KCArbourMD @MSKCancerCenter #AACR25 @KRASKickers

[Mark Awad @DrMarkAwad]

@MSKCancerCenter @AACR Congratulations to Dr. Arbour! Impressive results with a new targeted therapy (RMC-9805 / zoldonrasib) for our patients with KRAS G12D-mutant lung cancer @KCArbourMD @MSKCancerCenter @KRASKickers

[Mark Awad @DrMarkAwad]

@AACR @KCArbourMD @MSKCancerCenter Congratulations to @KCArbourMD and co-investigators for this exciting presentation on RMC-9805 zoldonrasib in KRAS G12D lung cancer @AACR @MSKCancerCenter